Patents by Inventor Shoki Hara

Shoki Hara has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrrolo[2,3-d]pyrimidines as EGFR inhibitors
    Patent number: 11786534
    Abstract: The present invention provides a novel compound inhibiting EGFR or a salt of the compound. According to one embodiment of the present invention, provided is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: October 17, 2023
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Fuyuki Yamamoto, Takashi Mizutani, Hidefumi Kasuga, Hirokazu Fuchida, Shoki Hara, Yu Kobayakawa, Yoshio Ogino
  • Sulfonamide compound or salt thereof
    Patent number: 11634395
    Abstract: The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.
    Type: Grant
    Filed: August 24, 2020
    Date of Patent: April 25, 2023
    Assignee: Taiho Pharmaceutial Co., Ltd.
    Inventors: Seiji Miyahara, Hiroyuki Ueno, Shoki Hara, Yoshio Ogino
  • 7H-PYRROLO[2,3-D]PYRIMIDINE-4-AMINE DERIVATIVE
    Publication number: 20220160719
    Abstract: The present invention provides a novel compound inhibiting EGFR or a salt of the compound. According to one embodiment of the present invention, provided is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 14, 2020
    Publication date: May 26, 2022
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Fuyuki YAMAMOTO, Takashi MIZUTANI, Hidefumi KASUGA, Hirokazu FUCHIDA, Shoki HARA, Yu KOBAYAKAWA, Yoshio OGINO
  • Sulfonamide compound or salt thereof
    Patent number: 10889555
    Abstract: The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: January 12, 2021
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Seiji Miyahara, Hiroyuki Ueno, Shoki Hara, Yoshio Ogino
  • Sulfonamide Compound or Salt Thereof
    Publication number: 20200399235
    Abstract: The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.
    Type: Application
    Filed: August 24, 2020
    Publication date: December 24, 2020
    Applicant: Taiho Pharmaceutical Co., Ltd.
    Inventors: Seiji Miyahara, Hiroyuki Ueno, Shoki Hara, Yoshio Ogino
  • Sulfonamide Compound or Salt Thereof
    Publication number: 20200157066
    Abstract: The present invention provides a novel sulfonamide compound having a ribonucleotide reductase inhibitory activity or a salt thereof, and a pharmaceutical composition containing the same as an active ingredient. A compound represented by Formula (I) [wherein, X1 represents an oxygen atom or the like; X2 represents an oxygen atom; X3 represents —NH—; X4 represents a hydrogen atom or the like; R1 represents —C(R11)(R12)— or the like; R11 and R12 are the same or different and each represents a hydrogen atom or the like; R2 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R3 represents an optionally substituted C6-C14 aromatic hydrocarbon group or the like; R4 represents a hydrogen atom or the like] or a salt thereof.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Applicant: Taiho Pharmaceutical Co., Ltd.
    Inventors: Seiji Miyahara, Hiroyuki Ueno, Shoki Hara, Yoshio Ogino